spacer
spacer

PDBsum entry 2oay

Go to PDB code: 
protein ligands links
Immune system,hydrolase inhibitor PDB id
2oay

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chain
368 a.a. *
Ligands
NAG
GOL ×3
Waters ×70
* Residue conservation analysis
PDB id:
2oay
Name: Immune system,hydrolase inhibitor
Title: Crystal structure of latent human c1-inhibitor
Structure: Plasma protease c1 inhibitor. Chain: a. Fragment: serpin domain. Synonym: c1-inhibitor. C1 inh. C1inh. C1 esterase inhibitor. C1- inhibiting factor. Engineered: yes. Mutation: yes
Source: Homo sapiens. Human. Organism_taxid: 9606. Gene: serping1, c1in, c1nh. Expressed in: pichia pastoris. Expression_system_taxid: 4922.
Resolution:
2.35Å     R-factor:   0.176     R-free:   0.218
Authors: V.Harmat,L.Beinrohr,P.Gal,J.Dobo
Key ref:
L.Beinrohr et al. (2007). C1 inhibitor serpin domain structure reveals the likely mechanism of heparin potentiation and conformational disease. J Biol Chem, 282, 21100-21109. PubMed id: 17488724 DOI: 10.1074/jbc.M700841200
Date:
18-Dec-06     Release date:   01-May-07    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chain
Pfam   ArchSchema ?
P05155  (IC1_HUMAN) -  Plasma protease C1 inhibitor from Homo sapiens
Seq:
Struc:
500 a.a.
368 a.a.*
Key:    PfamA domain  Secondary structure  CATH domain
* PDB and UniProt seqs differ at 2 residue positions (black crosses)

 

 
DOI no: 10.1074/jbc.M700841200 J Biol Chem 282:21100-21109 (2007)
PubMed id: 17488724  
 
 
C1 inhibitor serpin domain structure reveals the likely mechanism of heparin potentiation and conformational disease.
L.Beinrohr, V.Harmat, J.Dobó, Z.Lörincz, P.Gál, P.Závodszky.
 
  ABSTRACT  
 
C1 inhibitor, a member of the serpin family, is a major down-regulator of inflammatory processes in blood. Genetic deficiency of C1 inhibitor results in hereditary angioedema, a dominantly inheritable, potentially lethal disease. Here we report the first crystal structure of the serpin domain of human C1 inhibitor, representing a previously unreported latent form, which explains functional consequences of several naturally occurring mutations, two of which are discussed in detail. The presented structure displays a novel conformation with a seven-stranded beta-sheet A. The unique conformation of the C-terminal six residues suggests its potential role as a barrier in the active-latent transition. On the basis of surface charge pattern, heparin affinity measurements, and docking of a heparin disaccharide, a heparin binding site is proposed in the contact area of the serpin-proteinase encounter complex. We show how polyanions change the activity of the C1 inhibitor by a novel "sandwich" mechanism, explaining earlier reaction kinetic and mutagenesis studies. These results may help to improve therapeutic C1 inhibitor preparations used in the treatment of hereditary angioedema, organ transplant rejection, and heart attack.
 
  Selected figure(s)  
 
Figure 6.
FIGURE 6. Showcase of mutations. A, studies failed to detect any effect of the V458M polymorphism, although the conserved hydrophobic core (around strands s2B, s3B, and s4B) is involved (53). The reason is that the side chain of Met^458 (space-filled) sits in the biggest cavity of rC1-inh (orange cloud); hence, spatial differences are tolerated. B, the A436T mutation affects a residue whose side chain becomes buried upon RCL incorporation. Similar mutants of other serpins usually result in cleavable noninhibitory serpins, because loop insertion is hindered. Unexpectedly, the A436T mutant C1-inh is found predominantly in noncleavable loop-inserted forms (51). In the modeled mutant structure, the side chain of Thr^436 forms a novel hydrogen bond network with the side chain of His^421 and the backbone of Gln^422. This makes the RCL-inserted protein more stable.
Figure 7.
FIGURE 7. Different mechanisms of the polyanion potentiation of serpins. Serpins are shown as ellipses, proteinases as circles, and polyanions as lines in this schematic representation. Charged binding regions on proteins are marked with black and charge signs. A, the most prominent type of serpin activation by the "bridging" mechanism is depicted (19, 20). Antithrombin binds tightly to a specific site on the heparin chain. Thrombin binds to the same chain, but with lower affinity. Only thrombin diffuses one-dimensionally toward antithrombin until the encounter. Even then, they bind to different segments on heparin. B, the similar "co-occupation" mechanism proposed for protein C inhibitor is shown (29). Protein C inhibitor and protein C bind to the same polyanion chain, but neither binds with high affinity. Both proteins migrate along the chain until the encounter. In the Michaelis complex, they bind to the same site on the polyanion. C, the "sandwich" mechanism is shown. C1-inh binds a short polyanion with low affinity. Binding neutralizes surface charge at a specific region. Proteinase is now attracted to this surface, which happens to be the contact site in the encounter complex.
 
  The above figures are reprinted by permission from the ASBMB: J Biol Chem (2007, 282, 21100-21109) copyright 2007.  
  Figures were selected by an automated process.  

Literature references that cite this PDB file's key reference

  PubMed id Reference
20804470 A.Bygum, C.R.Fagerberg, D.Ponard, N.Monnier, J.Lunardi, and C.Drouet (2011).
Mutational spectrum and phenotypes in Danish families with hereditary angioedema because of C1 inhibitor deficiency.
  Allergy, 66, 76-84.  
19783065 R.Wallis, D.A.Mitchell, R.Schmid, W.J.Schwaeble, and A.H.Keeble (2010).
Paths reunited: Initiation of the classical and lectin pathways of complement activation.
  Immunobiology, 215, 1.  
19894781 G.M.Keating (2009).
Human C1-esterase inhibitor concentrate (Berinert).
  BioDrugs, 23, 399-406.  
19178150 L.Yang, M.F.Sun, D.Gailani, and A.R.Rezaie (2009).
Characterization of a heparin-binding site on the catalytic domain of factor XIa: mechanism of heparin acceleration of factor XIa inhibition by the serpins antithrombin and C1-inhibitor.
  Biochemistry, 48, 1517-1524.  
19162547 M.Cugno, A.Zanichelli, F.Foieni, S.Caccia, and M.Cicardi (2009).
C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress.
  Trends Mol Med, 15, 69-78.  
19522701 T.A.Murray-Rust, F.K.Kerr, A.R.Thomas, T.Wu, T.Yongqing, P.C.Ong, N.S.Quinsey, J.C.Whisstock, I.C.Wagenaar-Bos, C.Freeman, and R.N.Pike (2009).
Modulation of the proteolytic activity of the complement protease C1s by polyanions: implications for polyanion-mediated acceleration of interaction between C1s and SERPING1.
  Biochem J, 422, 295-303.  
18674818 A.E.Davis, P.Mejia, and F.Lu (2008).
Biological activities of C1 inhibitor.
  Mol Immunol, 45, 4057-4063.  
  18765903 J.Dobó, V.Harmat, E.Sebestyén, L.Beinrohr, P.Závodszky, and P.Gál (2008).
Purification, crystallization and preliminary X-ray analysis of human mannose-binding lectin-associated serine protease-1 (MASP-1) catalytic region.
  Acta Crystallogr Sect F Struct Biol Cryst Commun, 64, 781-784.  
18460017 L.Varga, G.Széplaki, J.Laki, A.Kocsis, K.Kristóf, P.Gál, Z.Bajtay, J.Wieslander, M.R.Daha, P.Garred, H.O.Madsen, G.Füst, and H.Farkas (2008).
Depressed activation of the lectin pathway of complement in hereditary angioedema.
  Clin Exp Immunol, 153, 68-74.  
18035961 M.Cicardi, L.C.Zingale, A.Zanichelli, D.L.Deliliers, and S.Caccia (2007).
The use of plasma-derived C1 inhibitor in the treatment of hereditary angioedema.
  Expert Opin Pharmacother, 8, 3173-3181.  
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time.

 

spacer

spacer